Nek7 conformational flexibility and inhibitor binding probed through protein engineering of the R-spine.


Journal

The Biochemical journal
ISSN: 1470-8728
Titre abrégé: Biochem J
Pays: England
ID NLM: 2984726R

Informations de publication

Date de publication:
30 04 2020
Historique:
received: 29 02 2020
revised: 02 04 2020
accepted: 03 04 2020
pubmed: 4 4 2020
medline: 15 12 2020
entrez: 4 4 2020
Statut: ppublish

Résumé

Nek7 is a serine/threonine-protein kinase required for proper spindle formation and cytokinesis. Elevated Nek7 levels have been observed in several cancers, and inhibition of Nek7 might provide a route to the development of cancer therapeutics. To date, no selective and potent Nek7 inhibitors have been identified. Nek7 crystal structures exhibit an improperly formed regulatory-spine (R-spine), characteristic of an inactive kinase. We reasoned that the preference of Nek7 to crystallise in this inactive conformation might hinder attempts to capture Nek7 in complex with Type I inhibitors. Here, we have introduced aromatic residues into the R-spine of Nek7 with the aim to stabilise the active conformation of the kinase through R-spine stacking. The strong R-spine mutant Nek7SRS retained catalytic activity and was crystallised in complex with compound 51, an ATP-competitive inhibitor of Nek2 and Nek7. Subsequently, we obtained the same crystal form for wild-type Nek7WT in apo form and bound to compound 51. The R-spines of the three well-ordered Nek7WT molecules exhibit variable conformations while the R-spines of the Nek7SRS molecules all have the same, partially stacked configuration. Compound 51 bound to Nek2 and Nek7 in similar modes, but differences in the precise orientation of a substituent highlights features that could be exploited in designing inhibitors that are selective for particular Nek family members. Although the SRS mutations are not required to obtain a Nek7-inhibitor structure, we conclude that it is a useful strategy for restraining the conformation of a kinase in order to promote crystallogenesis.

Identifiants

pubmed: 32242624
pii: 222565
doi: 10.1042/BCJ20200128
pmc: PMC7200626
doi:

Substances chimiques

Enzyme Inhibitors 0
NEK2 protein, human EC 2.7.11.1
NEK7 protein, human EC 2.7.11.1
NIMA-Related Kinases EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1525-1539

Subventions

Organisme : Medical Research Council
ID : MR/L017032/2
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C24461/A10285
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C24461/A13231
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L017032/1
Pays : United Kingdom

Informations de copyright

© 2020 The Author(s).

Références

Sci Rep. 2019 Dec 24;9(1):19790
pubmed: 31875044
Biochim Biophys Acta. 2015 Oct;1854(10 Pt B):1586-94
pubmed: 25936518
Front Cell Dev Biol. 2017 Dec 01;5:102
pubmed: 29250521
Elife. 2014 May 27;3:e02667
pubmed: 24867643
Acta Crystallogr D Biol Crystallogr. 2013 Jul;69(Pt 7):1204-14
pubmed: 23793146
J Proteome Res. 2014 Sep 5;13(9):4074-90
pubmed: 25093993
J Biol Chem. 2016 Jan 1;291(1):103-9
pubmed: 26553871
EMBO J. 2018 Apr 13;37(8):
pubmed: 29510984
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
Biochim Biophys Acta. 2010 Mar;1804(3):440-4
pubmed: 19879387
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):235-42
pubmed: 21460441
Nat Commun. 2015 Nov 02;6:8771
pubmed: 26522158
J Biol Chem. 2007 Mar 2;282(9):6833-42
pubmed: 17197699
J Cell Sci. 2011 Nov 15;124(Pt 22):3760-70
pubmed: 22100915
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):355-67
pubmed: 21460454
PLoS One. 2017 Aug 2;12(8):e0181585
pubmed: 28767711
Mol Cell. 2009 Nov 25;36(4):560-70
pubmed: 19941817
Mol Cell Biol. 2009 Jul;29(14):3975-90
pubmed: 19414596
Mol Cell. 2017 Mar 2;65(5):818-831.e5
pubmed: 28216227
Protein Sci. 2009 Oct;18(10):2016-26
pubmed: 19610074
Sci Signal. 2019 Aug 13;12(594):
pubmed: 31409757
J Cell Sci. 2020 May 11;133(9):
pubmed: 32184261
Molecules. 2015 Jan 13;20(1):1176-91
pubmed: 25591119
J Med Chem. 2010 Nov 11;53(21):7682-98
pubmed: 20936789
Nature. 2019 Jun;570(7761):338-343
pubmed: 31189953
Oncotarget. 2017 Mar 21;8(12):19089-19124
pubmed: 27833088
J Mol Biol. 2009 Feb 20;386(2):476-85
pubmed: 19124027
FEBS J. 2017 Sep;284(18):2947-2954
pubmed: 28342286
Sci Signal. 2013 Jul 02;6(282):ra54
pubmed: 23821772
J Med Chem. 2011 Jun 23;54(12):4133-46
pubmed: 21627121
Cell Cycle. 2015;14(4):656-67
pubmed: 25664600
J Cell Sci. 2012 Oct 1;125(Pt 19):4423-33
pubmed: 23132929
Nat Chem Biol. 2017 Apr;13(4):402-408
pubmed: 28166210
J Med Chem. 2012 Apr 12;55(7):3228-41
pubmed: 22404346
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
Medchemcomm. 2017 Dec 8;9(1):44-66
pubmed: 30108900
Nat Chem Biol. 2015 Jul;11(7):496-503
pubmed: 26030730
Acta Crystallogr D Biol Crystallogr. 2002 Nov;58(Pt 11):1948-54
pubmed: 12393927
Mol Biol Cell. 2017 Jul 15;28(15):2123-2134
pubmed: 28539406
Nat Immunol. 2016 Mar;17(3):250-8
pubmed: 26642356
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):271-81
pubmed: 21460445
Mol Cell Biol. 2015 Jan;35(1):264-76
pubmed: 25348715
J Med Chem. 2011 Mar 24;54(6):1626-39
pubmed: 21366329
Open Biol. 2012 Nov;2(11):120136
pubmed: 23226601
Nat Chem Biol. 2010 Mar;6(3):166-169
pubmed: 20154661
Acta Crystallogr D Biol Crystallogr. 2008 Sep;64(Pt 9):909-18
pubmed: 18703838
Acta Crystallogr D Struct Biol. 2018 Feb 1;74(Pt 2):85-97
pubmed: 29533234
Nature. 2016 Feb 18;530(7590):354-7
pubmed: 26814970

Auteurs

Matthew J Byrne (MJ)

Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, U.K.

Nazia Nasir (N)

Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, U.K.

Christine Basmadjian (C)

Newcastle University Centre for Cancer, School of Natural and Environmental Sciences, Newcastle University, Newcastle Upon Tyne, U.K.

Chitra Bhatia (C)

Department of Molecular and Cell Biology, University of Leicester, Leicester, U.K.

Rory F Cunnison (RF)

Department of Molecular and Cell Biology, University of Leicester, Leicester, U.K.

Katherine H Carr (KH)

Department of Molecular and Cell Biology, University of Leicester, Leicester, U.K.

Corine Mas-Droux (C)

Section of Structural Biology, The Institute of Cancer Research, London, U.K.

Sharon Yeoh (S)

Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, U.K.

Céline Cano (C)

Newcastle University Centre for Cancer, School of Natural and Environmental Sciences, Newcastle University, Newcastle Upon Tyne, U.K.

Richard Bayliss (R)

Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, U.K.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH